Please login to the form below

Deal Watch table for December 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during December 2014.

For an indepth analysis of these deals, read 'Pharma deals during December 2014'

Licensor acquired / licensee acquirer	Product / technology	Deal type	Headline ($m)
Cubist / Merck & Co	Portfolio of marketed and late stage antibiotics	Company acquisition	9,500
Avanir Pharmaceuticals / Otsuka Pharmaceutical	Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect	Company acquisition	3,500
*Astellas/ J&J	ASP015K, an oral JAK inhibitor for RA (p3)	Exercise of opt-out/ termination	**945
Macrogenics / J&J	MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical)	Licence	700
Cytokinetics / Astellas Pharma	CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1)	Expansion of collaboration/ amended agreement	675
Halozyme Therapeutics / J&J	ENHANZE rHuPH20 delivery technology for up to 5 targets	Collaboration, licence	581
Opko Health / Pfizer	Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3)	Licence	570
Adocia / Eli Lilly	BioChaperone Lispro (ultra-rapid insulin) based on BioChaperone technology (p1b)	Licence, collaboration	570
Dutalys / Roche	DutaMab technology for development of fully human, bispecific antibodies	Company acquisition	489
PneumRx / BTG	Portfolio of medical devices for interventional pulmonology inc RePneu Coil	Company acquisition	475
***GeNeuro / Servier	GNbAC1, mab to inhibit progression of MS without suppressing the immune system (p2)	Collaboration, option to license + take equity stake	455
Zosano Pharma / Eli Lilly	ZP-PTH (parathyroid hormone 1-34) delivered via microneedle patch system (p2)	Licence	440
OncoEthix / Merck & Co	Lead product oral BET inhibitor, OTX015 for oncology indications (p1b)	Company acquisition	375
Evotec / Sanofi	R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists)	Exclusive negotiations to create 5-year strategic alliance	310
Array BioPharma / Oncothyreon	ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1)	Licence - amended agreement	†300
Spark Therapeutics / Pfizer	Multiple haemophilia B gene therapy products (preclinical)	Gene therapy collaboration	280
Xencor / Novo Nordisk	XmAb technologies, inc bispecific and immune inhibitor technologies, for undisclosed target	Collaboration, licence	175
Phylogica / Genentech	Phylomer drug discovery platform for novel antibiotics	Research & licensing agreement	142.5
Boston Heart Diagnostics / Eurofins Scientific	Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes	Company acquisition	140
Sevion Therapeutics / J&J	Spatially addressed antibody discovery platform	Research collaboration, options to license	125
††Ariad Pharmaceuticals / Otsuka Pharmaceutical	Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph+ALL (JP NDA)	Co-development and commercialisation agreement	77.5

All deals global unless otherwise stated:

* ex Japan
** original deal headline value
***ex US, JP
† If Oncothyreon is acquired with 3 years of effective date, Array eligible for up to $280m milestones
†† JP + 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph+ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia)